Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
← catalyst calendarNCT05626712 · readout in 165 d
Sponsored by Creative Medical Technology Holdings Inc (industry) · CELZ — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
18estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-07 | actual | When the study began enrolling |
| Primary completion | 2027-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Type 1 Diabetes
- Diabetes Mellitus, Type 1
Interventions
- Biological: CELZ-201 Administration
- Other: Control Group
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Adverse Events
measured 6 months
Permalink · CELZ's whole pipeline · Catalyst calendar · Every registered study · What changed